Intensity Therapeutics jumps after Nasdaq grants compliance extension

Intensity Therapeutics

05/12/2025 12:40

** Shares of drugmaker Intensity Therapeutics INTS.O rise 8.6% to 50 cents premarket

** Co gets 180-day extension from the Nasdaq exchange to meet the minimum $1 share price requirement

** Deadline set for June 1, 2026; shares must stay above $1 for 10 consecutive days, says co

** Co continues late-stage trials of INT230-6 for soft tissue sarcoma and breast cancer

** INT230-6 is injected into tumors to kill cancer cells and trigger immune response - INTS

** Up to last close, stock down ~74% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))